# Korsana Biosciences Inc. (KRSA) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $31.96, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Korsana Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 701.8×**. Each dollar of revenue is priced at 701.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 160.2×**. The shares trade at 160.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Operating margin: -239.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -170.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -38.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -35.3%**. Each dollar of assets produces -35.3% of profit.

## Growth
- **Revenue growth (1 yr): 3.7%** (3-yr 91.1%/yr, 5-yr -2.0%/yr). Revenue grew 3.7% over the last year, against -2.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 8.3%**. Earnings per share rose 8.3%, roughly in step with revenue.

## Financial health
- **Current ratio: 5.15** (quick 5.15). Current assets cover the next year's liabilities 5.15 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Korsana Biosciences Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 141.9%** (YTD 256.1%, 3-mo 29.6%). The shares are up 141.9% over twelve months including dividends.
- **From 52-week high: -46.2%** (344.6% above the low). Trading 46% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 2.05** (volatility 328%). Beta of 2.05 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KRSA · Page: https://foliofundamentals.com/stocks/krsa

Not investment advice.